Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q2 FY23 results · Jul–Sep 2022
Alivus Life Sciences reported revenue from operations of ₹509.30 crore (down 9.3% from Q2 FY22) and net profit of ₹106.88 crore (down 7.2% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 509.30 | 561.76 | −9.3% | 489.87 | +4.0% |
| Other income | 10.02 | 2.09 | +379.7% | 9.49 | +5.6% |
| Total income | 519.32 | 563.85 | −7.9% | 499.36 | +4.0% |
| Profit before tax | 143.59 | 152.53 | −5.9% | 146.25 | −1.8% |
| Net profit for the period | 106.88 | 115.20 | −7.2% | 108.73 | −1.7% |
| EPS, basic (₹) | 8.72 | 9.83 | −11.3% | 8.87 | −1.7% |
| Net margin (%) | 21.0 | 20.5 | 22.2 |
Standalone
- Filed with BSE
- 24 Oct 2022, 15:50 IST
- Board meeting
- 21 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE